房颤患者经皮冠状动脉介入治疗12个月后停止抗血小板治疗真的安全吗?

IF 0.2 0 PHILOSOPHY Interventional Cardiology Review Pub Date : 2023-01-01 DOI:10.15420/icr.2022.40
Balen Abdulrahman, Richard J Jabbour, Nick Curzen
{"title":"房颤患者经皮冠状动脉介入治疗12个月后停止抗血小板治疗真的安全吗?","authors":"Balen Abdulrahman,&nbsp;Richard J Jabbour,&nbsp;Nick Curzen","doi":"10.15420/icr.2022.40","DOIUrl":null,"url":null,"abstract":"<p><p>The prevalence of AF in patients with coronary artery disease is high. The guidelines from many professional groups, including the European Society of Cardiology, American College of Cardiology/American Heart Association and Heart Rhythm Society, recommend a maximum duration of 12 months of combination single antiplatelet and anticoagulation therapy in patients who undergo percutaneous coronary intervention and who have concurrent AF, followed by anticoagulation alone beyond 1 year. However, the evidence that anticoagulation alone without antiplatelet therapy adequately reduces the well-documented attritional risk of stent thrombosis after coronary stent implantation is relatively sparse, particularly given that very late stent thrombosis (>1 year from stent implantation) is the commonest type. By contrast, the elevated risk of bleeding from combined anticoagulation and antiplatelet therapy is clinically important. The aim of this review is to assess the evidence for long-term anticoagulation alone without antiplatelet therapy 1 year post-percutaneous coronary intervention in patients with AF.</p>","PeriodicalId":38586,"journal":{"name":"Interventional Cardiology Review","volume":"18 ","pages":"e22"},"PeriodicalIF":0.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/db/13/icr-18-e22.PMC10331563.pdf","citationCount":"0","resultStr":"{\"title\":\"Is It Really Safe to Discontinue Antiplatelet Therapy 12 Months After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation?\",\"authors\":\"Balen Abdulrahman,&nbsp;Richard J Jabbour,&nbsp;Nick Curzen\",\"doi\":\"10.15420/icr.2022.40\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The prevalence of AF in patients with coronary artery disease is high. The guidelines from many professional groups, including the European Society of Cardiology, American College of Cardiology/American Heart Association and Heart Rhythm Society, recommend a maximum duration of 12 months of combination single antiplatelet and anticoagulation therapy in patients who undergo percutaneous coronary intervention and who have concurrent AF, followed by anticoagulation alone beyond 1 year. However, the evidence that anticoagulation alone without antiplatelet therapy adequately reduces the well-documented attritional risk of stent thrombosis after coronary stent implantation is relatively sparse, particularly given that very late stent thrombosis (>1 year from stent implantation) is the commonest type. By contrast, the elevated risk of bleeding from combined anticoagulation and antiplatelet therapy is clinically important. The aim of this review is to assess the evidence for long-term anticoagulation alone without antiplatelet therapy 1 year post-percutaneous coronary intervention in patients with AF.</p>\",\"PeriodicalId\":38586,\"journal\":{\"name\":\"Interventional Cardiology Review\",\"volume\":\"18 \",\"pages\":\"e22\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/db/13/icr-18-e22.PMC10331563.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Interventional Cardiology Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15420/icr.2022.40\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"0\",\"JCRName\":\"PHILOSOPHY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interventional Cardiology Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/icr.2022.40","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"0","JCRName":"PHILOSOPHY","Score":null,"Total":0}
引用次数: 0

摘要

房颤在冠心病患者中的发病率很高。包括欧洲心脏病学会、美国心脏病学会/美国心脏协会和心律学会在内的许多专业团体的指南建议,对于接受经皮冠状动脉介入治疗并并发房颤的患者,单抗血小板和抗凝治疗的最长持续时间为12个月,随后1年以上单独抗凝治疗。然而,单用抗凝治疗而不使用抗血小板治疗能充分降低有充分证据证明的冠状动脉支架植入术后支架血栓形成的损耗风险的证据相对较少,特别是考虑到极晚支架血栓形成(支架植入术后>1年)是最常见的类型。相比之下,抗凝和抗血小板联合治疗的出血风险升高具有重要的临床意义。本综述的目的是评估房颤患者经皮冠状动脉介入治疗1年后单独长期抗凝治疗而不使用抗血小板治疗的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Is It Really Safe to Discontinue Antiplatelet Therapy 12 Months After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation?

The prevalence of AF in patients with coronary artery disease is high. The guidelines from many professional groups, including the European Society of Cardiology, American College of Cardiology/American Heart Association and Heart Rhythm Society, recommend a maximum duration of 12 months of combination single antiplatelet and anticoagulation therapy in patients who undergo percutaneous coronary intervention and who have concurrent AF, followed by anticoagulation alone beyond 1 year. However, the evidence that anticoagulation alone without antiplatelet therapy adequately reduces the well-documented attritional risk of stent thrombosis after coronary stent implantation is relatively sparse, particularly given that very late stent thrombosis (>1 year from stent implantation) is the commonest type. By contrast, the elevated risk of bleeding from combined anticoagulation and antiplatelet therapy is clinically important. The aim of this review is to assess the evidence for long-term anticoagulation alone without antiplatelet therapy 1 year post-percutaneous coronary intervention in patients with AF.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Interventional Cardiology Review
Interventional Cardiology Review Medicine-Cardiology and Cardiovascular Medicine
CiteScore
0.30
自引率
0.00%
发文量
18
审稿时长
12 weeks
期刊最新文献
Wire Escalation And De-escalation Techniques in Antegrade and Retrograde Approaches to Chronic Total Occlusion Percutaneous Coronary Interventions. British Cardiovascular Intervention Society Training Culture Focus Group Position Statement: Bringing Trainees and Trainers Together. Atherectomy Techniques: Rotablation, Orbital and Laser. Outcomes and Complications of Mitral and Tricuspid Transcatheter Edge-to-edge Repair. New-generation Leadless Pacemaker Implantation: First Procedures in Central Asia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1